{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:54:26Z","timestamp":1789152866297,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11883-020-00865-5","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T01:02:41Z","timestamp":1594861361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis"],"prefix":"10.1007","volume":"22","author":[{"given":"Marco","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G.","family":"Chiabrando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni M.","family":"Vescovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Bressi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Giuseppe","family":"Del Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W.","family":"Van Tassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Biondi-Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-9521","authenticated-orcid":false,"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"865_CR1","doi-asserted-by":"publisher","unstructured":"Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics\u20142017. Update. 135:2017. https:\/\/doi.org\/10.1161\/CIR.0000000000000485.Heart.","DOI":"10.1161\/CIR.0000000000000485.Heart"},{"key":"865_CR2","doi-asserted-by":"publisher","unstructured":"Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2017;136(3). https:\/\/doi.org\/10.1161\/CIR.0000000000000510.","DOI":"10.1161\/CIR.0000000000000510"},{"issue":"9740","key":"865_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0140-6736(10)60445-X","volume":"376","author":"P Saravanan","year":"2010","unstructured":"Saravanan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376(9740):540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(10)60445-X.","journal-title":"Lancet."},{"issue":"4","key":"865_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MOL.0b013e3283616364","volume":"24","author":"CL Chang","year":"2013","unstructured":"Chang CL, Deckelbaum RJ. Omega-3 fatty acids: mechanisms underlying \u2018protective effects\u2019 in atherosclerosis. Curr Opin Lipidol. 2013;24(4):345\u201350. https:\/\/doi.org\/10.1097\/MOL.0b013e3283616364.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"865_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pcad.2018.03.006","volume":"61","author":"A Elagizi","year":"2018","unstructured":"Elagizi A, Lavie CJ, Marshall K, DiNicolantonio JJ, O'Keefe JH, Milani RV. Omega-3 polyunsaturated fatty acids and cardiovascular health : a comprehensive review. Prog Cardiovasc Dis. 2018;61(1):76\u201385. https:\/\/doi.org\/10.1016\/j.pcad.2018.03.006.","journal-title":"Prog Cardiovasc Dis"},{"key":"865_CR6","volume-title":"Network meta-analysis: evidence synthesis with mixed treatment comparison","author":"G Biondi-Zoccai","year":"2014","unstructured":"Biondi-Zoccai G. In: Biondi-Zoccai G, editor. Network meta-analysis: evidence synthesis with mixed treatment comparison. New York: Nova publishers; 2014."},{"key":"865_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.23736\/S0026-4725.19.05117-X","volume":"68","author":"M Lombardi","year":"2020","unstructured":"\u2022 Lombardi M, Chiabrando JG, Vescovo GM, et al. Efficacy of different dose of omega 3 fatty acid on cardiovascular outcomes: rationale and design of a network meta-analysis. Minerva Cardioangiol. 2020;68:47\u201350. https:\/\/doi.org\/10.23736\/S0026-4725.19.05117-XRationale and design of the present meta-analysis.","journal-title":"Minerva Cardioangiol"},{"issue":"7447","key":"865_CR8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1136\/bmj.38068.557998.ee","volume":"328","author":"RB Haynes","year":"2004","unstructured":"Haynes RB, Wilczynski NL. Optimal search strategies for retrieving scientifically strong studies of diagnosis from Medline: analytical survey. Br Med J. 2004;328(7447):1040\u20132. https:\/\/doi.org\/10.1136\/bmj.38068.557998.ee.","journal-title":"Br Med J"},{"key":"865_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:1\u20138. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"1","key":"865_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"\u2022 Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792In REDUCE-IT among patients with high trygliceride levels the risk of ischemic events was significantly lower among those who received 4 g\/daily of O3FA.","journal-title":"N Engl J Med"},{"key":"865_CR11","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/nejmc1014112","volume":"363","author":"D Kromhout","year":"2010","unstructured":"Kromhout D, Giltay EJ, Geleijnse JM. For the AOTG. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015\u201326. https:\/\/doi.org\/10.1056\/nejmc1014112.","journal-title":"N Engl J Med"},{"issue":"16","key":"865_CR12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1804989.","journal-title":"N Engl J Med"},{"issue":"1","key":"865_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JAE Manson","year":"2019","unstructured":"Manson JAE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1811403.","journal-title":"N Engl J Med"},{"issue":"9645","key":"865_CR14","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","volume":"372","author":"GISSI-HF investigators","year":"2008","unstructured":"GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(08)61239-8.","journal-title":"Lancet."},{"issue":"9177","key":"865_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","volume":"354","author":"R Marchioli","year":"1999","unstructured":"Marchioli R. Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(99)07072-5.","journal-title":"Lancet."},{"issue":"9567","key":"865_CR16","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"\u2022 Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(07)60527-3JELIS trial demonstrated tha 1.8 g\/daily of EPA is protective for prevention of coronary events in Japanese hypercholesterolaemic patients.","journal-title":"Lancet"},{"key":"865_CR17","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","volume":"122","author":"B Rauch","year":"2010","unstructured":"Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.948562.","journal-title":"Circulation."},{"issue":"5","key":"865_CR18","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/HJR.0b013e328339cc70","volume":"17","author":"G Einvik","year":"2010","unstructured":"Einvik G, Ole Klemsdal T, Sandvik L, Hjerkinn EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Prev Cardiol. 2010;17(5):588\u201392. https:\/\/doi.org\/10.1097\/HJR.0b013e328339cc70.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"865_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamainternmed.2014.328","volume":"174","author":"DE Bonds","year":"2014","unstructured":"Bonds DE, Harrington M, Worrall BB, et al. Effect of long-chain \u03c9-3 fatty acids and lutein+zeaxanthin supplements on cardiovascular outcomes: results of the age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA Intern Med. 2014;174(5):763\u201371. https:\/\/doi.org\/10.1001\/jamainternmed.2014.328.","journal-title":"JAMA Intern Med"},{"issue":"7787","key":"865_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/bmj.c6273","volume":"342","author":"P Galan","year":"2011","unstructured":"Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. Bmj. 2011;342(7787):36. https:\/\/doi.org\/10.1136\/bmj.c6273.","journal-title":"Bmj."},{"issue":"19","key":"865_CR21","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","volume":"368","author":"MC Roncaglioni","year":"2013","unstructured":"Roncaglioni MC, Tombesi M, Avanzini F, et al. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1205409.","journal-title":"N Engl J Med"},{"issue":"4","key":"865_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"J Bosch","year":"2012","unstructured":"Bosch J, Gerstein HC, Dagenais GR, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1203859.","journal-title":"N Engl J Med"},{"issue":"22","key":"865_CR23","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1001\/jama.295.22.2613","volume":"295","author":"IA Brouwer","year":"2006","unstructured":"Brouwer IA, Zock PL, Camm AJ, B\u00f6cker D, Hauer RN, Wever EF, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients. Jama. 2006;295(22):2613\u20139.","journal-title":"Jama."},{"key":"865_CR24","doi-asserted-by":"publisher","unstructured":"Wiggins BS, Dixon D, Bellone J, Gasbarro N, Marrs JC, Tran R. Key articles and guidelines in the management of dyslipidemia: 2019 update. J Pharm Pract. 2019:089719001986841. https:\/\/doi.org\/10.1177\/0897190019868413.","DOI":"10.1177\/0897190019868413"},{"key":"865_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurheartj\/ehz455","volume":"2019","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;2019:1\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"5","key":"865_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pcad.2019.10.008","volume":"62","author":"WS Harris","year":"2019","unstructured":"Harris WS. Understanding why REDUCE-IT was positive \u2013 mechanistic overview of eicosapentaenoic acid. Prog Cardiovasc Dis. 2019;62(5):401\u20135. https:\/\/doi.org\/10.1016\/j.pcad.2019.10.008.","journal-title":"Prog Cardiovasc Dis"},{"issue":"5","key":"865_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.pcad.2019.11.003","volume":"62","author":"V Bittner","year":"2019","unstructured":"Bittner V. Implications for REDUCE IT in clinical practice. Prog Cardiovasc Dis. 2019;62(5):395\u2013400. https:\/\/doi.org\/10.1016\/j.pcad.2019.11.003.","journal-title":"Prog Cardiovasc Dis"},{"issue":"10","key":"865_CR28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","volume":"122","author":"MD Shapiro","year":"2018","unstructured":"Shapiro MD, Tavori H, Fazio S. PCSK9 from basic science discoveries to clinical trials. Circ Res. 2018;122(10):1420\u201338. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311227.","journal-title":"Circ Res"},{"issue":"1","key":"865_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0887-0","volume":"18","author":"O Sheikh","year":"2019","unstructured":"Sheikh O, Vande Hei AG, Battisha A, Al E. Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. Cardiovasc Diabetol. 2019;18(1):1\u201312. https:\/\/doi.org\/10.1186\/s12933-019-0887-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"865_CR30","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1017\/S000711451300425X","volume":"111","author":"JK Wachira","year":"2014","unstructured":"Wachira JK, Larson MK, Harris WS. N-3 fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr. 2014;111(9):1652\u201362. https:\/\/doi.org\/10.1017\/S000711451300425X.","journal-title":"Br J Nutr"},{"issue":"4","key":"865_CR31","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/ajcn\/nqz161","volume":"110","author":"RE Walker","year":"2019","unstructured":"\u2022 Walker RE, Jackson KH, Tintle NL, et al. Predicting the effects of supplemental EPA and DHA on the omega-3 index. Am J Clin Nutr. 2019;110(4):1034\u201340. https:\/\/doi.org\/10.1093\/ajcn\/nqz161This predictive model demonstrated that a dose \u2265 2 g\/daily of O3FA is protective against CV events.","journal-title":"Am J Clin Nutr"},{"key":"865_CR32","doi-asserted-by":"publisher","unstructured":"Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. J Am Heart Assoc. 2019;8(19). https:\/\/doi.org\/10.1161\/jaha.119.013543.","DOI":"10.1161\/jaha.119.013543"},{"key":"865_CR33","doi-asserted-by":"publisher","unstructured":"Innes JK, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiometabolic risk factors: a systematic review. Int J Mol Sci. 2018;19(2). https:\/\/doi.org\/10.3390\/ijms19020532.","DOI":"10.3390\/ijms19020532"},{"key":"865_CR34","unstructured":"Ito MK. A comparative overview of prescription omega-3 fatty acid products. P T. 2015;40(12):826\u2013836."},{"issue":"10","key":"865_CR35","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/clc.23055","volume":"41","author":"SJ Nicholls","year":"2018","unstructured":"\u2022 Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41(10):1281\u20138. https:\/\/doi.org\/10.1002\/clc.23055Ongoing trial regarding high dose O3FA supplementation has been stopped due to futility.","journal-title":"Clin Cardiol"},{"key":"865_CR36","doi-asserted-by":"publisher","unstructured":"Weintraub WS, Bhatt D, Zhang Z, et al. Cost-effectiveness of icosapent ethyl in US REDUCE-IT patients. J Am Coll Cardiol. 2020;75(11, Suppl 1). https:\/\/doi.org\/10.1016\/S0735-1097(20)32541-9.","DOI":"10.1016\/S0735-1097(20)32541-9"},{"issue":"13","key":"865_CR37","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","volume":"74","author":"DL Dixon","year":"2019","unstructured":"Dixon DL, Sharma G, Sandesara PB, Yang E, Braun LT, Mensah GA, et al. Therapeutic inertia in cardiovascular disease prevention: time to move the bar. J Am Coll Cardiol. 2019;74(13):1728\u201331.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00865-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00865-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00865-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:56:34Z","timestamp":1626396994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00865-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["865"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00865-5","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"16 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"None of the authors have any disclosure related to the contents of this paper. Salvatore Carbone is supported by a Career Development Award 19CDA34660318 from the American Heart Association. Marco Lombardi, Juan G. Chiabrando, Giovanni M. Vescovo, Edoardo Bressi, Marco Giuseppe Del Buono, Salvatore Carbone, Rachel Koenig, Benjamin W. Van Tassell, Dave L. Dixon, Antonio Abbate, and Giuseppe Biondi-Zoccai declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"45"}}